European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
August 15, 2024 04:30 ET
|
Alvotech
The approvals process is anticipated to be completed in the third quarter of 2025 REYKJAVIK, Iceland and LONDON, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company...
Lyfjastofnun Evrópu tekur til umsagnar umsókn um markaðsleyfi fyrir AVT06, fyrirhugaða líftæknilyfjahliðstæðu við Eylea
August 15, 2024 04:30 ET
|
Alvotech
Markaðsleyfi fyrir Evrópu gæti verið veitt á þriðja fjórðungi næsta árs Alvotech (NASDAQ: ALVO) og samstarfsaðili þess, alþjóðlega lyfjafyrirtækið Advanz Pharma tilkynntu í dag að Lyfjastofnun...
European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
August 15, 2024 04:30 ET
|
Alvotech
The approvals process is anticipated to be completed in the third quarter of 2025 Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar...
Celebrating Second Chances for National Tattoo Removal Day
August 14, 2024 18:02 ET
|
Astanza Laser
Dallas, Aug. 14, 2024 (GLOBE NEWSWIRE) -- In a world where self-expression is paramount, National Tattoo Removal Day, observed annually on August 14th, shines a spotlight on the evolving landscape...
SciSparc Updates Regarding the Status of the AutoMax Merger
August 14, 2024 16:53 ET
|
SciSparc Ltd
SciSparc provides investors with an update regarding the status of the merger agreement with AutoMax, including the court’s approval of AutoMax’s petition to convene special class meetings of its...
XWELL, Inc. Reports Second Quarter 2024 Results
August 14, 2024 16:30 ET
|
XWELL, Inc.
NEW YORK, Aug. 14, 2024 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), an authority in wellness solutions for people on the go, today reported results for the second...
Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
August 14, 2024 16:25 ET
|
Inhibikase Therapeutics
BOSTON and ATLANTA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor...
LifeVantage to Announce Fourth Quarter and Full Fiscal Year 2024 Results on August 28, 2024
August 14, 2024 16:05 ET
|
LifeVantage Corporation
SALT LAKE CITY, Aug. 14, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the...
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer
August 14, 2024 16:01 ET
|
Turnstone Biologics Corp.
ORR of 25% and 50% DCR observed in first four evaluable patients treated with TIDAL-01 with advanced CRC
scPharmaceuticals Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024 16:01 ET
|
scPharmaceuticals, Inc.
Generated 2Q 2024 net FUROSCIX® revenue of $8.1 million, up 33% sequentially from Q1 Completed financing that extends our cash runway through expected profitability Advanced multiple FUROSCIX...